{"title": "Psoriasis: A Comprehensive Review on the Aetiopathogenesis and Recent Advances in Long-Term Management of Patients with Plaque Psoriasis", "author": "Tanja Gmeiner; Jasna Grzelj; Borut Strukelj; Luka Stopar; Pij Bogomir Marko; Scientific Research Publishing", "url": "https://www.scirp.org/journal/paperinformation.aspx?paperid=106331", "hostname": "scirp.org", "description": "Discover the latest breakthroughs in psoriasis treatment, from systemic inflammation control to personalized medicine. Explore the impact on comorbidities and long-term management, with insights from pharmacogenetics and biomarker identification. Uncover the potential for reducing cardiovascular risk and improving patient outcomes.", "sitename": "SCIRP", "date": "2020-12-15", "cleaned_text": "| [ |[1](../reference/referencespapers.aspx?referenceid=2898715)] | | Boehncke, W.-H., Boehncke, S., Tobin, A.-M. and Kirby, B. (2011) The \"Psoriatic March\": A Concept of How Severe Psoriasis May Drive Cardiovascular Comorbidity. Experimental Dermatology, 20, 303-307. https://doi.org/10.1111/j.1600-0625.2011.01261.x | [ |[2](../reference/referencespapers.aspx?referenceid=2898716)] | | Reich, K. (2012) The Concept of Psoriasis as a Systemic Inflammation: Implications for Disease Management. Journal of the European Academy of Dermatology and Venereology, 26, 3-11. https://doi.org/10.1111/j.1468-3083.2011.04410.x | [ |[3](../reference/referencespapers.aspx?referenceid=2898717)] | | Kerdel, F. and Don, F. (2018) The Importance of Early Treatment in Psoriasis and Management of Disease Progression. Journal of Drugs in Dermatology, 17, 737-742. | [ Shin, D.B., Wang, X., et al. (2007) The Risk of Mortality in Patients with Psoriasis: Results from a Population-Based Study. Archives of Dermatology, 143, 1493-1499. https://doi.org/10.1001/archderm.143.12.1493 | [ | C., Cappelleri, J.C., Mallbris, L., Petersson, I.F. and Stahle, M. (2015) Increased Cause-Specific Mortality in Patients with Mild and Severe Psoriasis: A Population-Based Swedish Register Study. Acta Dermato-Vene-reologica, 95, C.E.M. and Ashcroft, D.M. (2013) Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. Journal of Investigative Dermatology, 133, 377-385. https://doi.org/10.1038/jid.2012.339 | Griffiths, C.E. (2005) Psoriasis: Epidemiology, Clinical Features, and Quality of Life. Annals of the Rheumatic Diseases, 64, ii18-ii25. https://doi.org/10.1136/ard.2004.033217 | [ |[8](../reference/referencespapers.aspx?referenceid=2898722)] | | Queiro, R., Tej\u00f3n, P., Coto, P., Alonso, S., Alperi, M., Sarasqueta, C., et al. (2013) Clinical Differences between Men and Women with Psoriatic Arthritis: Relevance of the Analysis of Genes and Polymorphisms in the Major Histocompatibility Complex Region and of the Age at Onset of Psoriasis. Clinical and Developmental Immunology, 2013, Article ID: 482691. https://doi.org/10.1155/2013/482691 [ A., Afach, S., Doney, L., Dressler, C., Hua, C., et al. (2020) Systemic Pharmacological Treatments for Chronic Plaque Psoriasis: A Network Meta-Analysis. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD011535.pub3 A Classification of Psoriasis Vulgaris According to Phenotype. British Journal of Dermatology, 156, 258-262. https://doi.org/10.1111/j.1365-2133.2006.07675.x | [ |[11](../reference/referencespapers.aspx?referenceid=2898725)] | | Mrowietz, U. and Reich, K. (2009) Psoriasis\u2014New Insights into Pathogenesis and Treatment. Deutsches Arzteblatt International, P. and Gelfand, J.M. (2010) The Risk of Depression, Anxiety, and Suicidality in Patients with Psoriasis: A Population-Based Cohort study. Archives of Dermatology, 146, 891-895. https://doi.org/10.1001/archdermatol.2010.186 | [ |[13](../reference/referencespapers.aspx?referenceid=2898727)] | and Krueger, J.G. of Immunology, 227-255. https://doi.org/10.1146/annurev-immunol-032713-120225 | [ |[14](../reference/referencespapers.aspx?referenceid=2898728)] | | Nestle, F.O., Daniel, H., Kaplan, D.H. and Barker, J. (2009) Mechanism of Disease: Psoriasis. The New England Journal of Medicine, 361, 496-509. https://doi.org/10.1056/NEJMra0804595 | [ |[15](../reference/referencespapers.aspx?referenceid=2898729)] | | Henseler, T. and Christophers, E. (1995) Disease Concomitance in Psoriasis. Journal of the American Academy of Dermatology, 32, 982-986. https://doi.org/10.1016/0190-9622(95)91336-X | [ |[16](../reference/referencespapers.aspx?referenceid=2898730)] | | Henseler, T. and Christophers, E. (1985) Psoriasis of Early and Late Onset: Characterization of Two Types of Psoriasis Vulgaris. Journal of the American Academy of Dermatology, 13, 450-456. https://doi.org/10.1016/S0190-9622(85)70188-0 | [ |[17](../reference/referencespapers.aspx?referenceid=2898731)] | Melchi, C.F., Amerio, P., Girolomoni, G. and Abeni, D. (2004) Prevalence of Symptoms Experienced by Patients with Different Clinical Types of Psoriasis. British Journal of Dermatology, 151, 594-599. https://doi.org/10.1111/j.1365-2133.2004.06093.x | [ |[18](../reference/referencespapers.aspx?referenceid=2898732)] | | Alwan, W. and Nestle, F.O. (2015) Pathogenesis and Treatment of Psoriasis: Exploiting Pathopysiological Pathways for Precision Medicine. Clinical and Experimental Rheumatology, 33, S2-S6. | [ |[19](../reference/referencespapers.aspx?referenceid=2898733)] | | Reinholz, M., Schauber, J. (2012) Cathelicidin LL-37: An Antimicrobial Peptide with a Role in Inflammatory Skin Disease. Annals of Dermatology, 24, 126-135. https://doi.org/10.5021/ad.2012.24.2.126 | [ |[20](../reference/referencespapers.aspx?referenceid=2898734)] | | Facchinetti, V., Chatterjee, Wang, Y.-H., B., et al. Plasmacytoid |[21](../reference/referencespapers.aspx?referenceid=2898735)] | T. and Wof, P. (2019) Resolution of Plaque-Type Psoriasis: What Is Left behind (and Reinitiates the Disease). Seminars in Immunopathology, 41, 633-644. https://doi.org/10.1007/s00281-019-00766-z | [ |[22](../reference/referencespapers.aspx?referenceid=2898736)] | | Di G.K. and Nestle, F.O. (2011) The Multitasking Organ: Recent Insights into Skin Immune Function. Immunity, 35, 857-869. https://doi.org/10.1016/j.immuni.2011.12.003 | [ |[23](../reference/referencespapers.aspx?referenceid=2898737)] | | Schlapbach, C., Gehad, A., Yang, C., Watanabe, R., Guenova, E., Teague, J.E., et al. (2014) Human TH9 Cells Are Skin-Tropic and Have Autocrine and Paracrine Proinflammatory Science Translational |[24](../reference/referencespapers.aspx?referenceid=2898738)] | | Schon, M.P. and Erpenbeck, L. (2018) The Interleukin-23/Interleukin-17 Axis Links Adaptive and Innate Immunity in Psoriasis. Frontiers in Immunology, 9, 1323. https://doi.org/10.3389/fimmu.2018.01323 Wallbrecht, K., Gruber-Wackernagel, A., Wang, X.-J. and Wolf, P. (2013) Involvement of IL-9 in Th17-Associated Inflammation and Angiogenesis of Psoriasis. PLoS P.J., Smith, N., Margolis, D.J., Nijsten, T., et al. (2005) Epidemiology of Psoriatic Arthritis in the Population of the United States. Journal of the American Academy of Dermatology, 53, 573. https://doi.org/10.1016/j.jaad.2005.03.046 | [ |[27](../reference/referencespapers.aspx?referenceid=2898741)] | | Nijsten, T. and Wakkee, M. (2009) Complexity of the Association between Psoriasis and Comorbidities. Journal of Investigative Dermatology, 129, 1601-1603. https://doi.org/10.1038/jid.2009.55 | [ |[28](../reference/referencespapers.aspx?referenceid=2898742)] | | Yeung, H., Takeshita, J., Mehta, N.N., Kimmel, S.E., Ogdie, A., Margolis, D.J., et al. (2013) Psoriasis Severity and the Prevalence of Major Medical Comorbidity: A Population-Based Study. JAMA Dermatology, 149, Harskamp, C.T. and Armstrong, A.W. (2013) Psoriasis and Major Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Observational Studies. Journal of the American Heart Association, 2, e000062. https://doi.org/10.1161/JAHA.113.000062 | [ |[30](../reference/referencespapers.aspx?referenceid=2898744)] | | Augustin, M., Reich, K., Glaeske, G., Schaefer, I. and Radtke, M. (2010) Co-Morbidity and Age-Related Prevalence of Psoriasis: Analysis of Health Insurance Data in Germany. Acta Dermato-Venereologica, 90, 147-151. https://doi.org/10.2340/00015555-0770 | [ |[31](../reference/referencespapers.aspx?referenceid=2898745)] | | Kim, N., Thrash, B. and Menter, A. (2010) Comorbidities in Psoriasis Patients. Seminars in Cutaneous Medicine and Surgery, 29, 10-15. https://doi.org/10.1016/j.sder.2010.01.002 | [ |[32](../reference/referencespapers.aspx?referenceid=2898746)] | | Sterry, W., Strober, B.E., Menter, A. and International Psoriasis Council (2007) Obesity in Psoriasis: The Metabolic, Clinical and Therapeutic Implications. Report of an Interdisciplinary Conference and Review. British Journal of Dermatology, 157, 649-655. https://doi.org/10.1111/j.1365-2133.2007.08068.x | [ |[33](../reference/referencespapers.aspx?referenceid=2898747)] | | Farias, M.M., Achurra, P., Boza, C., Vega, A. and de la Cruz, C. (2012) Psoriasis Following Bariatric Surgery: Clinical Evolution and Impact on Quality of Life on 10 Patients. Obesity Surgery, 22, 877-880. https://doi.org/10.1007/s11695-012-0646-8 | [ |[34](../reference/referencespapers.aspx?referenceid=2898748)] | | C.D., Mowad, C.M. and Maroon, M.S. (2013) The Effect of Weight Loss Surgery on the Severity of Psoriasis. British Journal of Dermatology, 168, 660-661. https://doi.org/10.1111/j.1365-2133.2012.11211.x | [ |[35](../reference/referencespapers.aspx?referenceid=2898749)] | | Gisondi, P., Del Giglio, M., Di Francesco, V., Zamboni, M. and Girolomoni, G. (2008) Weight Loss Improves the Response of Obese Patients with Moderate-to-Severe Chronic Plaque Psoriasis to Low-Dose Cyclosporine Therapy: A Randomized, Controlled, Investigator-Blinded Clinical Trial. The American Journal of Clinical Nutrition, 88, 1242-1247. | [ |[36](../reference/referencespapers.aspx?referenceid=2898750)] | | Johnston, and Resistin as Mediators of Cutaneous Inflammation. of Dermatology, 342-350. | Kimball, Psoriasis Area Index (PASI) and the Dermatology Life Quality Index (DLQI): The Correlation between Disease Severity and Psychological Burden in Patients Treated with Biological Therapies. Journal of the European Academy of Dermatology and Venereology, 28, 333-337. https://doi.org/10.1111/jdv.12106 Kavanaugh, A., Langley, R.G., et al. (2014) Patient Perspectives in the Management of Psoriasis: Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. Journal of the American Academy of Dermatology, 70, 871-881. https://doi.org/10.1016/j.jaad.2013.12.018 | [ |[39](../reference/referencespapers.aspx?referenceid=2898753)] | | Mrowietz, U., de Jong, E.M., Kragballe, K., Langley, R., Nast, A., Puig, L., et al. (2014) A Consensus Report on Appropriate Treatment Optimization and Transitioning in the Management of Moderate-to-Severe Plaque Psoriasis. Journal of the European Academy of Dermatology and Venereology, 28, 438-453. https://doi.org/10.1111/jdv.12118 | [ |[40](../reference/referencespapers.aspx?referenceid=2898754)] | Kragballe, K., Reich, K., Spuls, P., Griffiths, C.E., Nast, A., et al. (2011) Definition of Treatment Goals for Moderate to Severe Psoriasis: A European Consensus. Archives of Dermatological Research, 303, 1-10. https://doi.org/10.1007/s00403-010-1080-1 | [ |[41](../reference/referencespapers.aspx?referenceid=2898755)] | | Strober, B., Ryan, C., van de Kerkhof, P., van der Walt, J., Kimball, A.B., Barker, J., et al. (2020) Recategorization of Psoriasis Severity: Delphi Consensus from the International Psoriasis Council. Journal of the American Academy of Dermatology, 82, 118-122. https://doi.org/10.1016/j.jaad.2019.08.026 | [ |[42](../reference/referencespapers.aspx?referenceid=2898756)] | | Gisondi, P., Del Giglio, M. and Girolomoni, G. (2017) Treatment Approaches to Moderate to Severe Psoriasis. Review. International Journal of Molecular Sciences, 18, 2427. https://doi.org/10.3390/ijms18112427 | [ |[43](../reference/referencespapers.aspx?referenceid=2898757)] | Mrowietz, U., Ockenfels, H.M., Philipp, S., Reich, K., et al. (2012) German S3-Guidelines on the Treatment of Psoriasis Vulgaris (Short Version). Archives of Dermatological Research, 304, 87-113. https://doi.org/10.1007/s00403-012-1214-8 | [ |[44](../reference/referencespapers.aspx?referenceid=2898758)] | A.D. and Yamauchi, P.S. (2016) Combining with Other Systemic Treatments in Psoriasis: Evidence-Based, Best-Practice Recommendations from the Medical Board of the National Psoriasis Foundation. JAMA Dermatology, 151, 432-438. https://doi.org/10.1001/jamadermatol.2014.3456 | M.L., Fleischer, A.B. and Reboussin, D.M. (1999) Psoriasis Causes as Much Disability as Other Major Medical Diseases. Journal of the American Academy of Dermatology, 41, 401-407. https://doi.org/10.1016/S0190-9622(99)70112-X | [ |[46](../reference/referencespapers.aspx?referenceid=2898760)] | | Fortune, D.G., Richards, H.L., Main, C.J. and Griffiths, C.E. (2002) Patients' Strategies for Coping with Psoriasis. Clinical and Experimental Dermatology, 27, 177-184. https://doi.org/10.1046/j.1365-2230.2002.01055.x Chalmers, al. (2009) British Association of Dermatologists' Guidelines for Biologic Interventions for Psoriasis 2009. British Journal of Dermatology, 161, 987-1019. https://doi.org/10.1111/j.1365-2133.2009.09505.x | [ |[48](../reference/referencespapers.aspx?referenceid=2898762)] | | Tlaker-Zunter, (2015) of Psoriasis. In: on Psoriasis, 73-83. (In Slovenian) [ |[49](../reference/referencespapers.aspx?referenceid=2898763)] | | Grzelj, J. and Sollner Dolenc, M. (2020) The Role of Xenobiotics in Triggering Psoriasis, Review. Archives of Toxicology, 94, 3959-3982. https://doi.org/10.1007/s00204-020-02870-8 | [ |[50](../reference/referencespapers.aspx?referenceid=2898764)] | | Wu, J.J., Poon, K.Y., Channual, J.C. and Shen, A.Y. (2012) Association between Tumor Necrosis Factor Inhibitor Therapy and Myocardial Infarction Risk in Patients with Psoriasis. Archives of Dermatology, 148, 1244-1250. https://doi.org/10.1001/archdermatol.2012.2502 | [ J., Franchin, G., Deambrosis, P., Giusti, P. and Chinellato, A. (2015) The Impact of Innovative Biologic Drugs in the Management of Psoriatic Patients. International Journal of Pharmacy and Pharmaceutical Sciences, 3, 43-49. http://www.openscienceonline.com/journal/osjpp | [ |[52](../reference/referencespapers.aspx?referenceid=2898766)] | | Ghoreschi, K., Gori, T., Kaya, Schaffler, A. (2020) IL-17A in Psoriasis NAD beyond: Cardiovascular and Metabolic Implications. Review. Frontiers in Immunology, 10, 3096. https://doi.org/10.3389/fimmu.2019.03096 | [ |[53](../reference/referencespapers.aspx?referenceid=2898767)] | | Mrowietz, U., Elder, J.T. and Barker, J. (2006) The Importance of Disease Associations and Concomitant Therapy for the Long-Term Management of Psoriasis Patients. Archives of Dermatological Research, 298, 309-319. https://doi.org/10.1007/s00403-006-0707-8 | [ |[54](../reference/referencespapers.aspx?referenceid=2898768)] | | Mrowietz, U., Steinz, K. and Gerdes, S. (2014) Psoriasis: To Treat or to Manage? Experimental Dermatology, 23, 705-709. Saiag, P., Smith, C., Spuls, P.I., Nast, A., et al. (2009) European S3-Guidelines on the Systemic Treatment of Psoriasis Vulgaris. Journal of the European Academy of Dermatology and Venereology, 23, 1-70. https://doi.org/10.1111/j.1468-3083.2009.03389.x Cordoro, K.M., D.M.R., al. (2020) Joint American Academy of Dermatologye National Psoriasis Foundation Guidelines of Care for the Management of Psoriasis with Systemic Nonbiologic Therapies. Journal of the American Academy of Dermatology, 82, 1444-1486. https://doi.org/10.1016/j.jaad.2020.02.044 | [ |[58](../reference/referencespapers.aspx?referenceid=2898772)] | | Sundaram, M., Thomason, D. and Signorovitch, J.E. (2016) Comparative Efficacy and Incremental Cost per Responder of Methotrexate versus Apremilast for Methotrexate-Naive Patients with Psoriasis. Journal of the American Academy of Dermatology, 75, 740-746. https://doi.org/10.1016/j.jaad.2016.05.040 | [ |[59](../reference/referencespapers.aspx?referenceid=2898773)] | | (2020) of Product Characteristics. https://mhraproducts4853.blob.core.windows.net/docs/5a585f38defdbb4817e0c4740df6a5bfc0e 4049b | [ |[60](../reference/referencespapers.aspx?referenceid=2898774)] | | Otezla (apremilast) (2020) Summary of Product Characteristics. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003746/WC500182627.pdf | [ |[61](../reference/referencespapers.aspx?referenceid=2898775)] | | Neoral (ciclosporin) (2020) Summary of Product Characteristics. |[62](../reference/referencespapers.aspx?referenceid=2898776)] | | (2020) Summary of Product Characteristic. Fachinfo Service. https://www.fachinfo.de/suche/fi/000847 | [ |[63](../reference/referencespapers.aspx?referenceid=2898777)] | | Methotrexate (2020) Summary of Product Characteristics. EMC. https://www.medicines.org.uk/emc/product/511/smpc#gref | [ |[64](../reference/referencespapers.aspx?referenceid=2898778)] | | Xeljanz (tofacitinib) (2020) Summary of Product Characteristics. European Medicines Agency. https://www.ema.europa.eu/en/documents/product-information/xeljanz-epar-product-information_en.pdf | [ |[65](../reference/referencespapers.aspx?referenceid=2898779)] | | Humira (adalimumab) (2020) Summary of Product Characteristic. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000481/WC500050870.pdf | [ |[66](../reference/referencespapers.aspx?referenceid=2898780)] | | Kyntheum (brodalumab) (2020) Summary of Product Characteristic. European Medicines Agency. https://www.ema.europa.eu/en/documents/product-information/kyntheum-epar-product-information_en.pdf | [ |[67](../reference/referencespapers.aspx?referenceid=2898781)] | | Enbrel (etanercept) (2020) Summary of Product Characteristics. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000262/WC500027361.pdf | [ |[68](../reference/referencespapers.aspx?referenceid=2898782)] | | Tremfya (guselkumab) (2020) Summary of Product Characteristics. European Medicines Agency. https://www.ema.europa.eu/en/documents/product-information/tremfya-epar-product-information_en.pdf | [ |[69](../reference/referencespapers.aspx?referenceid=2898783)] | | Remicade (infliximab) (2020) Summary of Product Characteristics. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000240/WC500050888.pdf | [ |[70](../reference/referencespapers.aspx?referenceid=2898784)] | | Taltz (ixekizumab) (2020) Summary of Product Characteristics. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003943/WC500205804.pdf | [ |[71](../reference/referencespapers.aspx?referenceid=2898785)] | | Skyrizi (risankizumab) (2020) Summary of Product Characteristics. European Medicines Agency. https://www.ema.europa.eu/en/documents/product-information/skyrizi-epar-product-information_en.pdf | [ |[72](../reference/referencespapers.aspx?referenceid=2898786)] | | Cosentyx (secukinumab) (2020) Summary of Product Characteristic. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003729/WC500183129.pdf | [ |[73](../reference/referencespapers.aspx?referenceid=2898787)] | | Ilumetri (tildrakizumab) (2020) Summary of Product Characteristics. European Medicines Agency. https://www.ema.europa.eu/en/documents/product-information/ilumetri-epar-product-information_en.pdf | [ |[74](../reference/referencespapers.aspx?referenceid=2898788)] | | Stelara (ustekinumab) (2020) Summary of Product Characteristics. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000958/WC500058513.pdf | [ |[75](../reference/referencespapers.aspx?referenceid=2898789)] | | Menter, A., (2017) Efficacy of Ixekizumab Compared to Etanercept and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis and Non-Pustular Palmoplantar Involvement: Results from Three Phase 3 Trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). Journal of the European Academy of Dermatology and Venereology, 31, 1686-1392. https://doi.org/10.1111/jdv.14237 | [ |[76](../reference/referencespapers.aspx?referenceid=2898790)] Gil, R.M., Ramos, B.S. and Paloma, F.J.B. (2013) Biological Treatments for Moderate-to-Severe Psoriasis: Indirect Comparison. Journal of Clinical Pharmacy and Therapeutics, 38, 121-130. https://doi.org/10.1111/jcpt.12044 | [ |[77](../reference/referencespapers.aspx?referenceid=2898791)] Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis. Journal of Investigative Dermatology, 137, 1646-1654. https://doi.org/10.1016/j.jid.2017.04.009 | [ |[78](../reference/referencespapers.aspx?referenceid=2898792)] | | Kim, I.H., West, C.E., Kwatra, S.G., Feldman, S.R. and O'Neill, J.L. (2012) Comparative Efficacy of Biologics in Psoriasis: A Review. American Journal of Clinical Dermatology, 13, 365-374. https://doi.org/10.2165/11633110-000000000-00000 | [ |[79](../reference/referencespapers.aspx?referenceid=2898793)] | | Gisondi, P., Tessari, G., Di Mercurio, M., Del Giglio, M. and Girolomo, G. (2013) Retention Rate of Systemic Drugs in Patients with Chronic Plaque Psoriasis. Clinics in Dermatology, 1, 8-14. | [ Hooft, L. and Spuls, P.I. (2014) Drug Survival Is Not Significantly Different between Biologics in Patients with Psoriasis Vulgaris: A Single-Centre Database Analysis. British Journal of Dermatology, 171, 875-883. https://doi.org/10.1111/bjd.13001 | [ |[81](../reference/referencespapers.aspx?referenceid=2898795)] | Bryld, L.E., Iversen, L., Lasthein, S. and Skov, L. (2015) Comparison of Long-Term Drug Survival and Safety of Biologic Agents in Patients with Psoriasis Vulgaris. British Journal of Dermatology, 172, 244-252. https://doi.org/10.1111/bjd.13343 | |[82](../reference/referencespapers.aspx?referenceid=2898796)] | | Gniadecki, R., Kragballe, K., Dam, T.N. and Skov, L. (2011) Comparison of Drug Survival Rates for Adalimumab, Etanercept and Infliximab in Patients with Psoriasis Vulgaris. of Dermatology, 164, 1091-1096. https://doi.org/10.1111/j.1365-2133.2011.10213.x | | Umezawa, Nobeyama, Y., Hayashi, M., Fukuchi, O., Ito, T., Saeki, H. and Nakagawa, H. (2013) Drug Survival Rates in Patients with Psoriasis after Treatment with Biologics. The Journal of Dermatology, 40, 1008-1013. https://doi.org/10.1111/1346-8138.12353 | [ | | Etanercept and Ustekinumab in Psoriasis in Daily Practice Care: Results from the BioCAPTURE Network. British Journal of Dermatology, 171, 1189. https://doi.org/10.1111/bjd.13087 | [ |[85](../reference/referencespapers.aspx?referenceid=2898799)] | Z.Z.N., Ashcroft, D.M., Barker, J.N.W.N., Burden, A.D., et al. (2015) Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 135, | Coope, H., McKenna, D.J. and Alexandroff, A. (2013) Long-Term Safety of Biologics in the Treatment of Psoriasis. Psoriasis: Targets and Therapy, 4, 1-9. https://doi.org/10.2147/PTT.S26168 | [ | | Nast, A., Ormerod, A.D., Saiag, P., Smith, C., Spuls, P.I., et al. (2015) European S3-Guidelines on the Systemic Treatment of Psoriasis Vulgaris\u2014Update 2015. Journal of the European Academy of Dermatology and Venereology, 29, 2277-2294. https://doi.org/10.1111/jdv.13354 | [ |[88](../reference/referencespapers.aspx?referenceid=2898802)] Gisondi, P., Geat, D., Pizzolato, M. and Girolomoni, G. (2019) State of the Art and Pharmacological Pipeline of Biologics for Chronic Plaque Psoriasis. Current Opinion in Pharmacology, 46, 90-99. https://doi.org/10.1016/j.coph.2019.05.007 | [ |[89](../reference/referencespapers.aspx?referenceid=2898803)] | | Lin, P.T., Wang, S.H. and Chi, C.C. (2018) Drug Survival of Biologics in Treating Psoriasis: A Meta-Analysis of Real-World Evidence. Scientific Reports, 8, Article No. 16068. https://doi.org/10.1038/s41598-018-34293-y | [ |[90](../reference/referencespapers.aspx?referenceid=2898804)] | Augustin, F.A., et al. (2016) Drug Survival of Biologic Therapy in a Large, Disease-Based Registry of Patients with Psoriasis: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Journal of the European Academy of Dermatology and Venereology, 30, 1148-1158. https://doi.org/10.1111/jdv.13611 | [ Cassano, N., Ferrucci, G., Del Giglio, M., Loconsole, F., et al. (2013) Survival Rate of Antitumour Necrosis Factor- Treatments for Psoriasis in Routine Dermatological Practice: A Multicentre Observational Study. British Journal of Dermatology, 169, 666-672. https://doi.org/10.1111/bjd.12422 Drug Survival of Biological Therapy Is Showing Class Effect: Update Results Form Slovenian National Registry of Psoriasis. International Journal of Dermatology, 58, 631-641. https://doi.org/10.1111/ijd.14429 | [ |[93](../reference/referencespapers.aspx?referenceid=2898807)] | | Egberg, A. and Skov, L. (2019) Drug Survival of Secukinumab and Ixekizumab for Moderate-to-Severe Plaque Psoriasis. Journal of the American Academy of Dermatology, 81, 173-178. https://doi.org/10.1016/j.jaad.2019.03.048 | [ |[94](../reference/referencespapers.aspx?referenceid=2898808)] | | Yiu, Mason, K.J., Hampton, P.J., Reynolds, N.J., Smith, C.H., Lunt, M., et al. (2020) Drug Survival of Adalimumab, Ustekinumab and Secukinumab in Patients with Psoriasis: A Prospective Cohort Study from the British Association of Dermatlologists Biologics and Immunomodulators Register (BADBIR). British Journal of 294-302. https://doi.org/10.1111/bjd.18981 | [ |[95](../reference/referencespapers.aspx?referenceid=2898809)] | | OMIM (2020) Online Mendelian Inheritance in Man. http://www.omim.org | [ |[96](../reference/referencespapers.aspx?referenceid=2898810)] | | J.L., Jones, A.B., Camp, R.D., Frodsham, A., et al. (1997) Identification of a Major Susceptibility Locus on Chromosome 6p and Evidence for Further Disease Loci Revealed by a Two Stage Genome-Wide Search in Psoriasis. Human Molecular Genetics, 6, 813-820. https://doi.org/10.1093/hmg/6.5.813 | [ |[97](../reference/referencespapers.aspx?referenceid=2898811)] | | Di Meglio, P., Villanova, F., Napolitano, L., Tosi, I., Terranova Barberio, Mak, Allele Promotes IL-23 in Human Cells and Impairs Th17 Responses in Psoriasis Patients. Journal of Investigative Dermatology, 133, 2381-2389. https://doi.org/10.1038/jid.2013.170 | [ |[98](../reference/referencespapers.aspx?referenceid=2898812)] | | Foulkes, A. and Warren, R. (2015) Pharmacogenomics and the Resulting Impact on Psoriasis Therapies. Dermatologic Clinics, 33, 146-160. https://doi.org/10.1016/j.det.2014.09.011 | [ |[99](../reference/referencespapers.aspx?referenceid=2898813)] | | Rahman, P., Inman, R.D., Gladman, D.D., Reeve, J.P., Peddle, L. and Maksymowych, (2008) Association of Interleukin-23 Receptor & | | Prieto-P\u00e9rez, R., Cabaleiro, T., Daud\u00e9n, E., Ochoa, D., Roman, M. and Abad-Santos, F. (2013) Genetics of Psoriasis and Pharmacogenetics of Biological Drugs. Autoimmune Diseases, 2013, Article ID: 613086. https://doi.org/10.1155/2013/613086 | [ |[101](../reference/referencespapers.aspx?referenceid=2898815)] | | Villanova, F., Di Meglio, P. and Nestle, F.O. (2013) Biomarkers in Psoriasis and Psoriatic Arthritis. Annals of the Rheumatic Diseases, 72, ii104-10. https://doi.org/10.1136/annrheumdis-2012-203037 | [ |[102](../reference/referencespapers.aspx?referenceid=2898816)] Chandran, V., Voorhees, J.J., Gladman, D.D., Rahman, P., et al. (2012) TNFAIP3 Gene Polymorphisms Are Associated with Response to TNF Blockade in Psoriasis. Journal of Investigative Dermatology, 1323, Galluzzo, M., Teoli, M., Spallone, M., al. (2013) Pharmacogenetics But Not LCE3B/3C Deletion nor TNFAIP3 Predisposes to Clinical Response to Interleukin 12/23 Blocker Ustekinumab. British Journal of Dermatology, 169, 458-463. https://doi.org/10.1111/bjd.12331 [ | | E., Eyre, S., Smith, C.H., Barker, J.N., et al. (2008) Genetic Variation in Efflux Transporters Influences Outcome to Methotrexate Therapy in Patients with Psoriasis. Journal of Investigative Dermatology, 128, 1925-1929. https://doi.org/10.1038/jid.2008.16 Daud\u00e9n, E. (2018) Pharmacogenetics and Pharmacogenmics in Moderate to Severe Psoriasis. American Journal of Clinical Dermatology, 19, 209-222. https://doi.org/10.1007/s40257-017-0322-9 | [ |[106](../reference/referencespapers.aspx?referenceid=2898820)] | | Pivarcsi, A., Meisgen, F., Xu, N., Stahle, M. and Sonkoly, E. (2013) Changes in the Level of Serum microRNAs in Patients with Psoriasis after Antitumour Necrosis Factor- Therapy. British Journal of Dermatology, 169, 563-570. https://doi.org/10.1111/bjd.12381 | [ |[107](../reference/referencespapers.aspx?referenceid=2898821)] | Orgaz-Molina, J., Magro-Checa, C., Valenzuela, I., Navarro, P., et al. (2014) Abnormal Levels of Expression of Plasma microRNA-33 in Patients with Psoriasis. Actas Dermo-Sifiliogr\u00e1ficas, Investigative Dermatology, 136, 365-371. https://doi.org/10.1038/JID.2015.409 | [ |[109](../reference/referencespapers.aspx?referenceid=2898823)] | | Frankel, H.C., Han, J., Li, T. and Qureshi, A.A. (2012) The Association between Physical Activity and the Risk of Incident Psoriasis. Archives "}